Bimekizumab Rates of Oral Candidiasis in Patients With Moderate to Severe Plaque Psoriasis: Results from up to 4 Years of Five Phase 3 3b Studies. J of Skin 2025, 9 (6), s646. https://doi.org/10.25251/ta5v8k92.